<DOC>
	<DOCNO>NCT00290004</DOCNO>
	<brief_summary>The primary purpose study evaluate safety , toxicity , dosage response rate investigational drug , motexafin gadolinium , administer patient chronic lymphocytic leukemia small lymphocytic lymphoma . The secondary purpose study evaluate clinical benefit rate , time take patient 's chronic lymphocytic leukemia small lymphocytic lymphoma worsen , duration response time patient survive without chronic lymphocytic leukemia small lymphocytic lymphoma worsen . Additionally , patient 's response motexafin gadolinium compare response patient 's cell laboratory motexafin gadolinium .</brief_summary>
	<brief_title>Study Weekly Motexafin Gadolinium ( MGd ) Patients With Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Motexafin gadolinium</mesh_term>
	<criteria>≥ 18 year old CLL define NCI 96 criterion ( exception ; patient may bright surface immunoglobulin stain negative [ 11 ; 14 ] translocation cyclin D1 ) SLL define WHO classification criterion refractory relapse defined one following : Refractory disease : progressive disease therapy Relapsed disease : progressive disease least one treatment course therapy disease response stabilization ECOG performance status score 0 , 1 , 2 Willing able provide write informed consent Laboratory value : Platelet count &lt; 30,000/µL AST ALT &gt; 2 x ULN ( upper limit normal ) Total bilirubin &gt; 2 x ULN Creatinine &gt; 2 mg/dL Chemotherapy , radiation therapy , immunotherapy , systemic corticosteroid ( &gt; 10 mg oral prednisone equivalent ) , systemic biologic anticancer therapy within 21 day begin study treatment Major surgery hospitalization serious illness within last 3 month Greater three prior regimen ( regimen define treatment CLL/SLL give initially disease progression ) Prior malignancy require current prior treatment within past 5 year , except cervical neoplasia situ nonmelanomatous skin cancer Uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Small Lymphocytic Lymphoma</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Motexafin Gadolinium</keyword>
	<keyword>Relapsed Chronic Lymphocytic Leukemia</keyword>
	<keyword>Relapsed Small Lymphocytic Lymphoma</keyword>
	<keyword>Refractory Chronic Lymphocytic Leukemia</keyword>
	<keyword>Refractory Small Lymphocytic Lymphoma</keyword>
</DOC>